{"type":"trials","record":{"id":41703,"source_id":"clinicaltrials-gov","external_id":"NCT07187804","title":"Long Term Efficacy of Faricimab Using a Treat and Extend Regimen for Type 3 Macular Neovascularization","brief_summary":"Type 3 macular neovascularization (MNV) is a subtype of neovascular age-related macular degeneration accounting for 10-20% of cases, notable for high rates of bilateral involvement and risk of profound vision loss, particularly if undertreated. Early and proactive therapy is crucial to prevent progression and preserve vision. Faricimab offers potential advantages in this setting. Eyes with type 3 MNV often show thin choroid, reticular pseudodrusen, and high GA risk, reflecting compromised choroidal perfusion. While anti-vascular endothelial growth factor (VEGF) agents suppress neovascularization, prolonged VEGF blockade may impair choriocapillaris health. Ang-2 inhibition, by promoting Tie2 activation and vascular stability, may protect choriocapillaris and reduce widespread retinal edema and hemorrhages observed in type 3 MNV. Finally, while treat-and-extend is widely used in practice, existing trials (TENAYA, LUCERNE) applied broader extension intervals than typically used clinically. In type 3 MNV, where undertreatment carries severe consequences, a more stringent faricimab-based treat-and-extend regimen with 2-week interval adjustments warrants investigation.","overall_status":"Not Yet Recruiting","phases":["PHASE4"],"study_type":"INTERVENTIONAL","sponsor":"Kim's Eye Hospital","enrollment":30,"countries":["South Korea"],"start_date":"2025-09-23","completion_date":"2028-09-22","last_update_date":"2025-09-23","source_url":"https://clinicaltrials.gov/study/NCT07187804","editorial_summary":"A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Not Yet Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years","comparator":null,"organization":"Kim's Eye Hospital","interventions":["Intravitreal faricimab injection"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Change in CST (central subfield thickness) — Baseline to week 76","Change in best-corrected visual acuity (BCVA) — Baseline to week 76","Choroidal thickness — Baseline to week 76","Geographic atrophy (GA) development — Baseline to week 76","Fluid resolution — Week 20, 52, and 76","Presence of neovascularization — Baseline, week 20, 52, and 76","Number of injection — Baseline to week 76","Maximum injection interval — Baseline to 76 weeks","Adverse event — Baseline to week 76"],"design_description":"NA · SINGLE GROUP · TREATMENT · NONE","source_has_results":false},"controlled_terms":["Age-related Macular Degeneration (ARMD)","Choroidal Neovascularization","Anti-vascular Endothelial Growth Factor","Intravitreal faricimab injection"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Abstract contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct07187804","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2025-09-23 to 2028-09-22","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.856Z","intervention":["Intravitreal faricimab injection"],"participants":30,"study_design":"NA · SINGLE GROUP · TREATMENT · NONE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE4","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Change in CST (central subfield thickness) — Baseline to week 76","Change in best-corrected visual acuity (BCVA) — Baseline to week 76","Choroidal thickness — Baseline to week 76","Geographic atrophy (GA) development — Baseline to week 76","Fluid resolution — Week 20, 52, and 76","Presence of neovascularization — Baseline, week 20, 52, and 76","Number of injection — Baseline to week 76","Maximum injection interval — Baseline to 76 weeks","Adverse event — Baseline to week 76"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Abstract supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["abstract","controlled terminology","abstract context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41703","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}